This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NuVasive (NUVA) to Expand in APAC With New Experience Center
by Zacks Equity Research
NuVasive's (NUVA) Singapore Experience Center will complement the flagship Experience Centers in San Diego and the New York metropolitan area.
Sanofi's (SNY) Studies on BTK Inhibitor Put on Hold by FDA
by Zacks Equity Research
Sanofi (SNY) pauses enrollment in late-stage studies evaluating its BTK inhibitor in multiple sclerosis and myasthenia gravis after the FDA places a partial clinical hold on these studies.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to its robust segmental results and the ongoing Cantel Medical integration.
Quest Diagnostics' (DGX) Base Business Grows Despite Margin Woes
by Zacks Equity Research
Quest Diagnostics (DGX) continues to make inroads with its health plans, gaining share and increasing revenues faster than the market.
Exact Sciences (EXAS) Cologuard Growth Robust Amid Margin Woes
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business is growing on impressive Cologuard volume growth and revenue contributions from the PreventionGenetics acquisition.
Omnicell (OMCL) Up 10% Since Q1 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Omnicell's (OMCL) strategic partnerships and continued innovations for the Autonomous Pharmacy.
Illumina's (ILMN) GRAIL to Offer Galleri Test in Indianapolis
by Zacks Equity Research
Illumina's (ILMN) division GRAIL will offer the Galleri MCED blood test to eligible patients across the Community Health Network's care sites.
Align (ALGN) Gains From Increased Case Shipment Amid FX Woes
by Zacks Equity Research
Align Technology's (ALGN) focus on expanding its global operations, both in existing and emerging international markets, raises optimism.
4 Reasons Why Investors Should Buy Merck (MRK) Stock Now
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and a solid pipeline are some key reasons to own Merck's (MRK) stock.
Charles River (CRL) Signs saRNA-Based Vaccine Manufacture Deal
by Zacks Equity Research
Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.
Here's Why Investors Should Retain Syneos Health (SYNH) For Now
by Zacks Equity Research
Investors about optimistic about Syneos Health's (SYNH) robust segmental performance and earnings outlook.
Sanofi (SNY) Wins Nod for Nexviadyme & Xenpozyme in Europe
by Zacks Equity Research
Sanofi's (SNY) Nexviadyme is approved for the treatment of both late-onset Pompe disease and infantile-onset Pompe disease. Xenpozyme is approved for non-Central Nervous System (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.
Here's Why Investors Should Retain CVS Health (CVS) For Now
by Zacks Equity Research
Investors are optimistic about CVS Health's (CVS) robust revenue growth across its operating segments.
Novartis (NVS) Gets Positive CHMP Opinion for Scemblix in CML
by Zacks Equity Research
The CHMP recommends approval of Novartis' (NVS) Scemblix for treating adult patients with chronic myeloid leukemia. EU also approves label expansion of Cosentyx.
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for New Indication
by Zacks Equity Research
The CHMP recommends approval of AbbVie's (ABBV) Rinvoq for treating adults with active non-radiographic axial spondyloarthritis.
Merck (MRK) Keytruda Gets Europe Nod for Expanded Melanoma Use
by Zacks Equity Research
European Commission approves Merck's (MRK) Keytruda as an adjuvant treatment for adults and adolescent patients with stage IIB or IIC melanoma and who have undergone complete resection.
3 Reasons Why Novo Nordisk (NVO) Is a Great Growth Stock
by Zacks Equity Research
Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.
The Zacks Analyst Blog Highlights Novo Nordisk, Toyota Motor, Salesforce, Abbott Laboratories, Raytheon Technologies, and Equinor
by Zacks Equity Research
Novo Nordisk, Toyota Motor, Salesforce, Abbott Laboratories, Raytheon Technologies, and Equinor are part of Zacks top Analyst Blog.
Top Research Reports for Novo Nordisk, Toyota & Salesforce
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Toyota Motor Corporation (TM), and Salesforce, Inc. (CRM).
Here's How Much a $1000 Investment in Novo Nordisk Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
The Zacks Analyst Blog Highlights Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group
by Zacks Equity Research
Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group have been included in this Analyst Blog.
Top Analyst Reports for Bank of America, Novo Nordisk, & Novartis
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Novo Nordisk A/S (NVO), and Novartis AG (NVS).
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.
4 Large Drug Stocks to Watch as the Industry Recovers
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.
Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod
by Zacks Equity Research
Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.